Company Name
Altimmune Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN:
US02155H2004
CIK:
0001326190
CUSIP:
42224H203
Currency:
USD
Full Time Employees:
59
Phone:
240 654 1450
Website:
https://altimmune.com
Fiscal Year End:
December
IPO Date:
Oct 06, 2005
Description:
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Address:
910 Clopper Road, Gaithersburg, MD, United States, 20878